Quest Diagnostics Receivables 2010-2024 | DGX

Quest Diagnostics receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
  • Quest Diagnostics receivables for the quarter ending June 30, 2024 were $1.319B, a 6.8% increase year-over-year.
  • Quest Diagnostics receivables for 2023 were $1.21B, a 1.26% increase from 2022.
  • Quest Diagnostics receivables for 2022 were $1.195B, a 16.9% decline from 2021.
  • Quest Diagnostics receivables for 2021 were $1.438B, a 5.39% decline from 2020.
Quest Diagnostics Annual Receivables
(Millions of US $)
2023 $1,210
2022 $1,195
2021 $1,438
2020 $1,520
2019 $1,063
2018 $1,012
2017 $924
2016 $926
2015 $901
2014 $932
2013 $852
2012 $867
2011 $906
2010 $845
2009 $827
Quest Diagnostics Quarterly Receivables
(Millions of US $)
2024-06-30 $1,319
2024-03-31 $1,322
2023-12-31 $1,210
2023-09-30 $1,281
2023-06-30 $1,235
2023-03-31 $1,254
2022-12-31 $1,195
2022-09-30 $1,280
2022-06-30 $1,293
2022-03-31 $1,371
2021-12-31 $1,438
2021-09-30 $1,473
2021-06-30 $1,255
2021-03-31 $1,382
2020-12-31 $1,520
2020-09-30 $1,421
2020-06-30 $1,126
2020-03-31 $972
2019-12-31 $1,063
2019-09-30 $1,117
2019-06-30 $1,088
2019-03-31 $1,079
2018-12-31 $1,012
2018-09-30 $1,097
2018-06-30 $1,055
2018-03-31 $1,026
2017-12-31 $924
2017-09-30 $960
2017-06-30 $947
2017-03-31 $960
2016-12-31 $926
2016-09-30 $966
2016-06-30 $975
2016-03-31 $952
2015-12-31 $901
2015-09-30 $914
2015-06-30 $937
2015-03-31 $949
2014-12-31 $932
2014-09-30 $953
2014-06-30 $963
2014-03-31 $977
2013-12-31 $852
2013-09-30 $921
2013-06-30 $947
2013-03-31 $930
2012-12-31 $867
2012-09-30 $931
2012-06-30 $941
2012-03-31 $974
2011-12-31 $906
2011-09-30 $936
2011-06-30 $929
2011-03-31 $940
2010-12-31 $845
2010-09-30 $884
2010-06-30 $870
2010-03-31 $865
2009-12-31 $827
2009-09-30 $888
2009-06-30 $897
2009-03-31 $888
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $17.308B $9.252B
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $21.379B 12.93
DaVita (DVA) United States $13.689B 16.84
Encompass Health (EHC) United States $9.303B 22.88
Chemed (CHE) United States $8.694B 26.73
Elanco Animal Health (ELAN) United States $7.242B 16.28
Option Care Health (OPCH) United States $5.321B 26.14
RadNet (RDNT) United States $4.963B 117.74
Amedisys (AMED) United States $3.181B 22.75
Astrana Health (ASTH) United States $2.805B 39.69
LifeStance Health (LFST) United States $2.579B 0.00
Addus HomeCare (ADUS) United States $2.399B 29.12
U.S Physical Therapy (USPH) United States $1.274B 34.50
Pennant (PNTG) United States $1.057B 50.71
Aveanna Healthcare Holdings (AVAH) United States $1.022B 0.00
Atai Life Sciences (ATAI) Germany $0.208B 0.00
Daxor (DXR) United States $0.045B 0.00
ATI Physical Therapy (ATIP) United States $0.025B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.019B 0.00
Psychemedics (PMD) United States $0.014B 0.00
Ontrak (OTRK) United States $0.010B 0.00
Novo Integrated Sciences (NVOS) United States $0.006B 0.00
IMAC Holdings (BACK) United States $0.002B 0.00